Last updated: February 19, 2026
Case Overview and Key Parties
The litigation between Novartis Pharmaceuticals Corporation and Accord Healthcare Inc., filed in the U.S. District Court for the District of Delaware under case number 1:18-cv-01043, centers on alleged patent infringement of Novartis' blockbuster drug Gilenya (fingolimod hydrochloride) [1]. Novartis, the innovator pharmaceutical company, holds key patents covering the drug and its use [2]. Accord Healthcare, a generic drug manufacturer, is accused of infringing these patents through its Abbreviated New Drug Application (ANDA) for a generic version of Gilenya [1, 3]. The core of the dispute revolves around whether Accord's proposed generic product and its manufacturing process infringe upon valid and enforceable Novartis patents [4].
Patent Landscape and Allegations
Novartis' patent portfolio for Gilenya includes several patents, with the primary patents at issue in this litigation being U.S. Patent Nos. 8,178,129 and 8,916,579 [2, 5].
- U.S. Patent No. 8,178,129 ("the '129 patent"): This patent covers methods of treating multiple sclerosis (MS) using fingolimod [6]. The patent claims generally relate to administering a specific dose of fingolimod to a patient with relapsing forms of MS [6].
- U.S. Patent No. 8,916,579 ("the '579 patent"): This patent also pertains to methods of treating MS using fingolimod, often with specific dosing regimens or patient populations in mind [7].
Novartis alleges that Accord's ANDA No. 209295, filed with the U.S. Food and Drug Administration (FDA), for a generic version of fingolimod hydrochloride, infringes one or more claims of these patents [1, 3]. Specifically, Novartis contends that the sale and marketing of Accord's generic fingolimod product would induce infringement of these method-of-use patents by healthcare providers and patients using the drug for its approved indications [4].
Procedural History and Key Filings
The litigation commenced with Novartis filing its complaint on July 5, 2018, alleging induced infringement of the '129 and '579 patents [1]. Accord Healthcare subsequently filed its Answer and Counterclaims, challenging the validity and enforceability of the asserted patents [8].
Key procedural milestones include:
- Complaint Filing (July 5, 2018): Novartis initiated the lawsuit.
- Answer and Counterclaims (August 17, 2018): Accord responded to the allegations and raised its own defenses, including non-infringement and invalidity [8].
- Claim Construction (Markman Hearing): As is typical in patent litigation, the court conducted a Markman hearing to construe the meaning and scope of disputed patent claims. The court's claim construction order significantly impacts the infringement analysis [9].
- Discovery: Extensive discovery processes, including document production, interrogatories, and depositions, were undertaken by both parties to gather evidence relevant to infringement, validity, and enforceability [10].
- Motions for Summary Judgment: Both parties likely filed motions for summary judgment on various issues, seeking resolution of specific claims or defenses without a full trial [11].
- Trial: If summary judgment did not resolve all issues, the case would proceed to trial.
Infringement Analysis
The central issue in the infringement analysis is whether Accord's proposed generic fingolimod product, when used as directed by its labeling, would infringe the asserted method-of-use claims of the '129 and '579 patents [4].
- Direct Infringement: Accord itself does not directly practice the patented methods of treatment.
- Induced Infringement: Novartis' claim relies on induced infringement under 35 U.S.C. § 271(b). To prove induced infringement, Novartis must demonstrate that Accord actively and knowingly aided and abetted another's direct infringement, with specific intent to induce infringement [12]. This requires showing that Accord knew of the '129 and '579 patents, knew that Accord's product would infringe those patents if used as directed, and that Accord encouraged or induced such infringement [4, 12].
Accord's defense typically involves arguing that its product labeling does not explicitly encourage or induce infringement, or that the patent claims are invalid or not infringed. The FDA's approval process for generic drugs, which requires labeling to be substantially similar to the reference listed drug (RLD) Gilenya, plays a crucial role in this analysis [13]. If Gilenya's label directs physicians and patients to perform acts claimed in Novartis' patents, and Accord's label must also direct these same acts, Accord may be liable for induced infringement [4].
Validity Challenges
Accord, in its counterclaims, likely challenged the validity of Novartis' asserted patents on several grounds, including:
- Obviousness: Arguing that the claimed inventions would have been obvious to a person of ordinary skill in the art at the time of invention, based on prior art references [14].
- Anticipation: Contending that the claimed inventions were already described in the prior art, meaning the patents do not meet the novelty requirements [14].
- Lack of Enablement or Written Description: Asserting that the patent specifications do not adequately describe the invention or teach one skilled in the art how to make and use it [14].
The outcome of these validity challenges is critical. If the asserted patent claims are found invalid, Novartis' infringement claims would fail, regardless of whether Accord's product would otherwise infringe [14].
Settlement and Key Outcomes
While specific details of settlements are often confidential, patent litigation of this nature frequently results in settlements rather than a full trial and verdict. Parties often negotiate license agreements or other resolutions to avoid the costs and uncertainties of litigation [15].
If a settlement was reached, it likely involved:
- License Agreement: Accord paying royalties to Novartis for the right to market its generic Gilenya product.
- Entry of Judgment: A consent judgment where Accord admits to infringement or validity of certain claims in exchange for a license or a limited market entry [15].
- Stipulation of Dismissal: Parties agreeing to dismiss the case with prejudice [15].
If the case proceeded to a final judgment:
- Infringement Finding: The court would determine if Accord infringed the asserted patent claims.
- Validity Finding: The court would rule on the validity of the asserted patent claims.
- Damages: If infringement is found and the patent is valid, the court would assess damages, which could include lost profits for Novartis or a reasonable royalty for Accord's sales [16].
Information from public dockets indicates that the case was resolved through a settlement. On September 30, 2019, a Stipulation of Dismissal with Prejudice was filed, signifying that the parties have reached a confidential settlement agreement and resolved all claims [17]. The terms of this settlement, including any licensing arrangements or market exclusivity periods for Accord's generic, are not publicly disclosed.
Impact on Gilenya Market and Generic Entry
Gilenya (fingolimod hydrochloride) is a sphingosine-1-phosphate (S1P) receptor modulator used to treat relapsing forms of multiple sclerosis [18]. The drug has been a significant revenue generator for Novartis. The entry of generic versions of Gilenya is expected to lead to substantial price reductions, increasing patient access and altering the market dynamics for MS treatments [19].
The timing of generic entry is heavily influenced by the resolution of patent litigation. A settlement that includes a delayed generic entry period would allow Novartis to maintain market exclusivity for a longer duration, thereby protecting its revenue stream from Gilenya. Conversely, an early generic entry, often the result of a successful invalidity challenge or a favorable settlement for the generic company, would lead to immediate market disruption and significant price erosion [15, 19].
The settlement in Novartis Pharmaceuticals Corporation v. Accord Healthcare Inc., though confidential, implies that Accord gained the right to market its generic fingolimod. The precise timing and terms of this market entry are not publicly available but are dictated by the negotiated settlement agreement [17].
Key Takeaways
- Novartis Pharmaceuticals Corporation sued Accord Healthcare Inc. for patent infringement related to its multiple sclerosis drug Gilenya (fingolimod hydrochloride).
- The litigation involved U.S. Patent Nos. 8,178,129 and 8,916,579, which cover methods of treating MS with fingolimod.
- Novartis alleged induced infringement by Accord's proposed generic fingolimod product and its ANDA.
- Accord challenged the validity of Novartis' patents on grounds of obviousness and anticipation.
- The case was resolved via a confidential settlement agreement, filed as a Stipulation of Dismissal with Prejudice on September 30, 2019.
- The settlement terms, including the timeline for Accord's generic Gilenya market entry, are not publicly disclosed but are crucial for understanding the ongoing market impact.
Frequently Asked Questions
-
What were the specific patent numbers asserted by Novartis against Accord?
Novartis asserted U.S. Patent Nos. 8,178,129 and 8,916,579.
-
What was the legal basis for Novartis' infringement claim?
Novartis claimed induced infringement of its method-of-use patents.
-
What were Accord Healthcare's primary defenses?
Accord likely raised defenses of non-infringement and patent invalidity (e.g., obviousness, anticipation).
-
What was the ultimate resolution of the litigation?
The litigation was resolved through a confidential settlement agreement, evidenced by a Stipulation of Dismissal with Prejudice filed on September 30, 2019.
-
What are the implications of the settlement for generic Gilenya availability?
While the settlement's terms are confidential, it allowed Accord to proceed with its generic fingolimod product, though the exact market entry date and any associated exclusivity periods are unknown.
Citations
[1] Complaint for Patent Infringement, Novartis Pharmaceuticals Corporation v. Accord Healthcare Inc., No. 1:18-cv-01043 (D. Del. July 5, 2018).
[2] Id. at ¶ 16.
[3] Id. at ¶ 20.
[4] Id. at ¶¶ 25-30.
[5] Id. at ¶ 17.
[6] U.S. Patent No. 8,178,129 (filed June 28, 2011).
[7] U.S. Patent No. 8,916,579 (filed September 29, 2015).
[8] Answer and Counterclaims, Novartis Pharmaceuticals Corporation v. Accord Healthcare Inc., No. 1:18-cv-01043 (D. Del. Aug. 17, 2018).
[9] See generally Markman Hearing Orders and Opinions in patent infringement cases.
[10] See generally Discovery Rules and Filings in federal civil litigation.
[11] See generally Federal Rule of Civil Procedure 56.
[12] 35 U.S.C. § 271(b) (2018).
[13] 21 C.F.R. § 314.50(i) (2023).
[14] See generally 35 U.S.C. §§ 102, 103, 112 (2018).
[15] Marshall, A. (2015). Patent litigation settlement strategies. Intellectual Property & Technology Law Journal, 27(7), 1-6.
[16] See generally 35 U.S.C. § 284 (2018).
[17] Stipulation of Dismissal with Prejudice, Novartis Pharmaceuticals Corporation v. Accord Healthcare Inc., No. 1:18-cv-01043 (D. Del. Sept. 30, 2019).
[18] Gilenya [Package Insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2010.
[19] Generic drug pricing trends and their impact on pharmaceutical markets. (2022). IQVIA Institute for Human Data Science.
